Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
Completed · Phase 3 · Has a placebo group
Conditions studied: Rosacea
In brief
This is a Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of facial erythema associated with rosacea.
Key facts
- Study ID
- NCT01355471
- Run by
- Galderma R&D
- People needed
- 293
- Starts
- 2011-05-01
- Expected to finish
- 2012-01-01
- Last updated by the study team
- 2021-02-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Burke Pharmaceutical Research — Hot Springs, Arkansas, United States
- Baumann Cosmetic and Research Institute — Miami Beach, Florida, United States
- MedaPhase, Inc. — Newnan, Georgia, United States
- Dermatology Specialists Research — Louisville, Kentucky, United States
- Grekin Skin Institute — Warren, Michigan, United States
- Central Dermatology PC — St Louis, Missouri, United States
- Skin Specialty Dermatology — New York, New York, United States
- Haber Dermatology & Cosmetic Surgery — South Euclid, Ohio, United States
- Oregon Dermatology and Research Center — Portland, Oregon, United States
- Palmetto Clinical Trial Services, LLC — Greenville, South Carolina, United States
- J&S Studies Inc. — College Station, Texas, United States
- Premier Clinical Research — Spokane, Washington, United States
- Kirk Barber Research Inc. — Calgary, Alberta, Canada
- Nexus Clinical Research — St. John's, Newfoundland and Labrador, Canada
- Newlab Clinical Research Inc. — St. John's, Newfoundland and Labrador, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.